Table 1.
Substitution | |
---|---|
Clinical or Treatment-Seeking or -Engaged | |
Alcohol use | Alcohol-related consequences |
Self-reported substitution of ALC with CB24 | |
CB use days associated with lower ALC consumption after ALC Tx25 | |
Decreased CB after contingency management Tx for CUD associated with increased ALC use; reinitiated CB associated with decreased ALC use26 | |
Non–Treatment-Seeking | |
Alcohol use | Alcohol-related consequences |
CB abstinence associated with increased ALC use7,8,41,42 | |
THC administration associated with increased ALC use and craving43 | |
Combined ALC and CB associated with lower “want more drug”57 | |
Complementary | |
Clinical or Treatment-Seeking or -Engaged | |
Alcohol use | Alcohol-related consequences |
CB use after AUD Tx associated with resumed ALC use16 | More frequent CB use during AUD Tx associated with increased ALC consequences 1 year after Tx19 |
CB at AUD Tx entry associated with reduced abstinence17 | CB use predicts AUD14,15 |
Mid-level CB use frequency during/after AUD Tx associated with fewer abstinent days after Tx, higher quantity, and greater frequency18,20 | |
Reduced CB use after CUD Tx associated with reduced ALC use among those with AUD21 | |
Reductions in ALC and CB use among persons in ALC Tx who report heavy drinking and CB use22,23 | |
Non–Treatment-Seeking | |
Alcohol use | Alcohol-related consequences |
Daily CB use associated with more ALC use27,28 | CB use associated with increased ALC consequences28,32–34,36 |
Simultaneous use associated with more ALC use6,10,30 | Co-use associated with neurocognitive abnormalities35 |
Note: ALC, alcohol; AUD, alcohol use disorder; CB, cannabis; CUD, cannabis use disorder; Tx, treatment